Korro Bio Announces Collaboration With Novo Nordisk To Develop Two Therapeutic Candidates, Leveraging Korro's Proprietary OPERA Platform To Enable Its Oligonucleotide-Directed RNA Edits Into Two Undisclosed Targets; Initially For Cardiometabolic Diseases; Total Deal Value Of Up To $530M In Upfront, Development, And Commercial Milestone Payments, In Addition To Tiered Royalties And R&D Funding

Partnership leverages Korro's proprietary OPERATM platform to enable its oligonucleotide-directed RNA edits into two undisclosed targets; initially for cardiometabolic diseases

Total deal value of up to $530 million in upfront, development, and commercial milestone payments, in addition to tiered royalties and R&D funding

CAMBRIDGE, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a potential new class of genetic medicines based on RNA editing for both rare and highly prevalent diseases, today announced a collaboration with Novo Nordisk, a global healthcare company, to advance the discovery and development of new genetic medicines, with the initial target to treat cardiometabolic diseases. The collaboration brings together Novo Nordisk's deep cardiometabolic disease understanding and drug development experience with Korro's proprietary platform to develop RNA editing product candidates for two undisclosed targets.